Immunophotonics Announces First Patient Dosed in Phase 2a Clinical Trial of IP-001 in advanced solid tumor indications
May 11, 2022
Immunophotonics announced that the first patient has been dosed in the phase 2a portion of its Swiss clinical trial for…
Immunophotonics HEC-TV Interview
May 5, 2022
Immunophotonics was interviewed by HEC-TV, St. Louis on our lead asset IP-001. Immunophotonics would not be where they are today…
Swiss Biotech Day May 2-3, 2022
May 5, 2022
The Immunophotonics Team is thrilled to announce that Dr. Theresa Visarius of Immunophotonics Switzerland (IPS Biopharma) will be presenting at…
US Oncology Research BioTech Day, Early Development Program Summit
May 5, 2022
Samuel Lam, PhD, Vice President of Science and Research at Immunophotonics, Inc. and Markus Joerger, MD, PhD, Clinical Trial Principal…
European Conference on Interventional Oncology (EICO 2022) April 24–27, 2022
April 26, 2022
Interested in learning how Immunophotonics, Inc. continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into…
Immunophotonics Announces Appointment of Miguel Zubizarreta to Its Board of Directors
April 15, 2022
Immunophotonics has strengthened its leadership with the appointment of Miguel Zubizarreta to its Board of Directors. Mr. Zubizarreta, a tech…
American Association for Cancer Research (AACR) Annual Meeting, April 8 – 13, 2022
April 14, 2022
Look for Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. in New Orleans at the American Association for…
Immunophotonics Raises $21.4 Million in Equity Financing for Phase 2 Clinical Trials
April 6, 2022
Immunophotonics continues to attract investments that will fund research and clinical trials regarding the use of the company’s lead drug…
Dr. Wei R. Chen Elected to the 2022 Class of the AIMBE College of Fellows
April 5, 2022
Lu Alleruzzo, CEO; Tomas Hode, CIO & President; and the Immunophotonics Team want to congratulate Dr. Wei Chen on being…
SIO Annual Scientific Meeting, March 24 -28, 2022
March 28, 2022
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. attended the SIO 2022 annual scientific meeting March 24 –…